[Bromazepam in the treatment of anxiety in nephrology and haemodialysis (author's transl)].
Bromazepam was tested in 15 patients with chronic renal failure undergoing haemodialysis and in 10 patients with normal renal function (controls). The initial dosage (6 mg/day) was modified according to anxiolytic response and sedative effects. Satisfactory results were obtained with 6 mg/day in patients under haemodialysis and in controls with reactional anxiety. Relief from anxiety-induced inhibitions and decrease in somatic disorders were observed. The drug was very well tolerated.
D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000209:etiology; D001960:Bromazepam / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy / Q000209:etiology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000523:psychology*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D014151:Anti-Anxiety Agents; D001960:Bromazepam
Intérêt du bromazépam dans le traitement de l'anxiété en néphrologie et hémodialyse.